Anusha Chidharla, MBBS, University of Kansas Medical Center, Kansas City, MO, shares the promising results of a real-world study on outcomes for VHL-associated tumors treated with belzutifan, demonstrating an improved objective response compared to initial clinical trials. Objective responses were seen in 78% of patients, including partial responses in 68% and complete responses in 14%. The disease control rate was 92% across all tumor types (renal cell cancer, pancreatic lesions, and CNS hemangioblastomas). Objective response rates were 23% for renal cell cancer, 53% for pancreatic lesions (including 10% complete response), and 23% for CNS hemangioblastomas. The most common side effects were anemia and fatigue (65-70%), nausea (25%), and dizziness and decrease in concentration (20%). Dose reduction was necessary in 30% of patients, and one patient discontinued due to side effects. Overall, belzutifan appears to be a promising and relatively safe systemic treatment option for patients with VHL-associated tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.